We are live on !
Find out more
Takeda Pharmaceutical Company Portfolio holdings
AUM
$16.4M
Turnover
27.27%
1-Year Est. Return
195.92%
This Fund
S&P 500
This Quarter Est. Return
+252.95%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.4M
AUM Growth
-$3.18M
(-16%)
Cap. Flow
-$13.7M
Cap. Flow % of AUM
Cap. Flow %
-83.98%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
–
Closed
3
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lyell Immunopharma
LYEL
|
+$157K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HilleVax
HLVX
|
+$13.4M |
| 2 |
Turnstone Biologics
TSBX
|
+$322K |
| 3 |
Third Harmonic Bio
THRD
|
+$200K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Ovid Therapeutics
OVID
$504M
| $9.8M | 59.82% |
7,531,996
| – | – |
2023 Q4
7 quarters
|
|
2
Equillium
EQ
$104M
| $2.61M | 15.94% |
1,824,977
| – | – |
2023 Q4
7 quarters
|
|
3
Xilio Therapeutics
XLO
$55.9M
| $1.24M | 7.59% |
105,366
| – | – |
2023 Q4
7 quarters
|
|
4
Shattuck Labs
STTK
$451M
| $1.23M | 7.53% |
515,619
| – | – |
2023 Q4
7 quarters
|
|
|
5
Lyell Immunopharma
LYEL
$368M
| $891K | 5.45% |
54,887
+13,722
| +33% | +$157K |
2024 Q4
3 quarters
|
|
6
American Well
AMWL
$206M
| $478K | 2.92% |
77,733
| – | – |
2023 Q4
7 quarters
|
|
7
Rani Therapeutics
RANI
$59.6M
| $102K | 0.62% |
203,190
| – | – |
2023 Q4
7 quarters
|
|
8
Standard BioTools
LAB
$246M
| $21.5K | 0.13% |
16,515
| – | – |
2023 Q4
7 quarters
|
|
|
9
DELISTED
HilleVax
HLVX
| – | – |
-6,724,000
| Closed | -$13.4M | – |
|
|
10
DELISTED
Third Harmonic Bio
THRD
| – | – |
-36,835
| Closed | -$200K | – |
|
|
11
DELISTED
Turnstone Biologics
TSBX
| – | – |
-895,824
| Closed | -$322K | – |
|
Similar funds
KL
LM
Takeda Pharmaceutical Company's Q3 2025 Portfolio in Review
As of Q3 2025, Takeda Pharmaceutical Company held 11 positions worth $16.4M, down 16% from $19.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Takeda Pharmaceutical Company withdrew a net $13.7M in Q3 2025, closing 3 positions. Its most notable exit was HilleVax, an estimated $13.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Takeda Pharmaceutical Company added an estimated $157K to Lyell Immunopharma.
- Takeda Pharmaceutical Company added most to Lyell Immunopharma in Q3 2025, an estimated $157K increase.
- Takeda Pharmaceutical Company fully exited HilleVax in Q3 2025, selling an estimated $13.4M.
- Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $16.4M portfolio in Q3 2025.
- Takeda Pharmaceutical Company opened 0 new positions and closed 3 in Q3 2025.
- Takeda Pharmaceutical Company's portfolio value fell 16% quarter-over-quarter to $16.4M.
Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.